The agency said it will evaluate whether further regulatory action is needed after investigating the deaths of two patients treated with Sarepta's Duchenne therapy.
The agency said it will evaluate whether further regulatory action is needed after investigating the deaths of two patients treated with Sarepta's Duchenne therapy.
